Adjuvant Atezolizumab Improves DFS Over Best Supportive Care in Stage IB-IIIA NSCLC

Compared with best supportive care, adjuvant atezolizumab improves disease-free survival (DFS) among patients with resected stage IB-IIIA non-small cell lung cancer (NSCLC), according to research being presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

In the phase 3 IMpower010 study (ClinicalTrials.gov Identifier: NCT02486718), researchers compared adjuvant atezolizumab to best supportive care in patients with stage IB-IIIA NSCLC who had undergone surgery and received adjuvant chemotherapy.

Of the 1280 patients who received a cisplatin-based chemotherapy regimen, 1005 patients were randomly assigned to receive either adjuvant atezolizumab (507 patients) or best supportive care (498 patients). 

The median follow-up time at data cutoff (January 2021) was 32.2 months in the intention-to-treat population. The median DFS was not reached in the atezolizumab group and was 37.2 months in the best supportive care group (hazard ratio, 0.81; P =.04).

In a subgroup of patients with stage II-IIIA disease, the median DFS was 42.3 months in the atezolizumab group (442 patients) and 35.3 months in the best supportive care group (440 patients; hazard ratio, 0.79; P =.02).

In a subgroup of patients with both stage II-IIIA disease and PD-L1 expression of at least 1%, the median DFS was not reached in the atezolizumab group (248 patients) and was 35.3 months in the best supportive care group (228 patients; hazard ratio, 0.66; P =.004).

Adverse events (AEs) of any grade occurred in 92.7% of patients in the atezolizumab group and 70.7% of patients in the best supportive care group. Grade 3-4 AEs occurred in 21.8% and 11.5% of patients, respectively.

AEs leading to treatment discontinuation occurred in 18.2% of patients in the atezolizumab group, and grade 5 treatment-related AEs occurred in 0.8% of patients in this group.

Future reports will provide overall survival data.

Disclosures: This research was supported by F. Hoffmann-La Roche. Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures. 

Reference

Wakelee H, Altorki N, Zhou C, et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39:(suppl 15; abstr 8500). doi:10.1200/JCO.2021.39.15_suppl.8500

This article originally appeared on Cancer Therapy Advisor